Live feed/
Filings
/
SCHEDULE 13D/A
/
0001213900-26-098957
Stake: 19.35%
Shares: 3,057,488
CUSIP: M4119S187
Class: Ordinary shares, par value NIS 0.20 per share
Composite Decision Signal · PASS (LOW BASE-RATE EDGE)
Conviction Score: 39/100
- Active Schedule 13D filer baseline
- 1 independent officer/director Code-P buyer ($292,100 in ±30d)
- High conviction ownership stake (19.4%)
Item 4 — Purpose of Transaction
Item 4 of the Schedule 13D is hereby amended to add the following at the end thereof: On September 8, 2026, the Reporting Persons delivered a letter to the Issuer notifying the Issuer that they, acting individually or jointly, intend to commence a special tender offer pursuant to Section 328 of the Israeli Companies Law, 5759-1999, which, if consummated, would result in the Reporting Persons holding, in the aggregate, not less than 25% of the Issuer's outstanding voting rights. A copy of the letter is attached hereto as Exhibit 9 and is incorporated herein by reference.
Cross-References
Insider Activity (last 365d)
1 transaction
1 buys · 0 sales · 0 awards/exercises
Issuer Cluster
11 13D/G filings on this issuer
10 other filings besides this one
Filer Track Record
16 filings by this filer
15 other filings in the data moat
Short Interest · settle 2026-10-15
DTC 1.00
63,883 shares short · -93.2% vs prior
Form 4 Insider Transactions · last 365d
| Date | Insider | Role | Type | Shares | Price | Value |
|---|
| 2026-08-11 |
RECANATI LEON |
director |
Buy |
460,000 |
$0.64 |
$292K |
Other 13D/G Filings on Evogene Ltd.
| Filed | Form | Filer | Stake | Shares | |
|---|
| 2026-10-06 |
SCHEDULE 13D/A |
L.I.A. Pure Capital Ltd |
— |
3,057,488 |
view → |
| 2026-09-11 |
SCHEDULE 13D/A |
RECANATI LEON |
8.60% |
1,354,836 |
view → |
| 2026-08-28 |
SCHEDULE 13D/A |
L.I.A. Pure Capital Ltd |
19.35% |
3,057,488 |
view → |
| 2026-08-13 |
SCHEDULE 13D/A |
RECANATI LEON |
8.60% |
1,354,836 |
view → |
| 2026-08-13 |
SCHEDULE 13D/A |
L.I.A. Pure Capital Ltd |
— |
3,057,488 |
view → |
| 2026-08-11 |
SCHEDULE 13D |
RECANATI LEON |
5.70% |
894,836 |
view → |
| 2026-08-07 |
SCHEDULE 13D/A |
L.I.A. Pure Capital Ltd |
15.98% |
2,524,400 |
view → |
| 2026-07-27 |
SCHEDULE 13D/A |
L.I.A. Pure Capital Ltd |
17.41% |
2,308,100 |
view → |
| 2026-07-20 |
SCHEDULE 13D/A |
L.I.A. Pure Capital Ltd |
— |
2,228,100 |
view → |
| 2026-07-10 |
SCHEDULE 13D |
L.I.A. Pure Capital Ltd |
12.61% |
1,526,100 |
view → |
Other Filings by L.I.A. Pure Capital Ltd
| Filed | Form | Issuer | Stake | Shares | |
|---|
| 2026-10-06 |
SCHEDULE 13D/A |
Evogene Ltd. |
— |
3,057,488 |
view → |
| 2026-08-28 |
SCHEDULE 13D/A |
Evogene Ltd. |
19.35% |
3,057,488 |
view → |
| 2026-08-13 |
SCHEDULE 13D/A |
Evogene Ltd. |
— |
3,057,488 |
view → |
| 2026-08-07 |
SCHEDULE 13D/A |
Evogene Ltd. |
15.98% |
2,524,400 |
view → |
| 2026-07-27 |
SCHEDULE 13D/A |
Evogene Ltd. |
17.41% |
2,308,100 |
view → |
| 2026-07-20 |
SCHEDULE 13D/A |
Evogene Ltd. |
— |
2,228,100 |
view → |
| 2026-07-10 |
SCHEDULE 13D |
Evogene Ltd. EVGN |
12.61% |
1,526,100 |
view → |
| 2025-06-04 |
SCHEDULE |
XYLO TECHNOLOGIES LTD |
5.66% |
2,900,000 |
view → |
| 2020-12-03 |
SC |
Therapix Biosciences Ltd. SPRC |
— |
— |
view → |
| 2020-07-01 |
SC |
Therapix Biosciences Ltd. SPRC |
— |
— |
view → |
| 2020-06-26 |
SC |
Therapix Biosciences Ltd. SPRC |
— |
— |
view → |
| 2020-06-09 |
SC |
Medigus Ltd. |
— |
— |
view → |
| 2020-06-09 |
SC |
Therapix Biosciences Ltd. SPRC |
— |
— |
view → |
| 2020-04-28 |
SC |
Medigus Ltd. |
— |
— |
view → |
| 2019-03-18 |
SC |
BOS BETTER ONLINE SOLUTIONS LTD BOSC |
— |
— |
view → |
Want this depth on every filing the moment it hits SEC EDGAR?
Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.
See pricing →